Holobiome, Inc.
Boston, US · Founded 2015 · Delaware corporation · 19 employees on LinkedIn · 10 known investors
Holobiome discovers and develops therapies derived from the human gut microbiome, working to translate microbiome science into probiotics and targeted treatments for whole-body health. The company was founded by research scientists from Northeastern University.
Founders & leadership
Holobiome, Inc. was founded in 2015 by Philip Strandwitz, Kim Lewis, and Mike La Fleur.
PS
Philip StrandwitzinCo-founder and CEO
KL
Kim LewisCo-founder, Director
ML
Mike La FleurPresident, Co-founder, Director
ML
Michael LaFleurExecutive
Board
JL
IC
Iain ChessellBoard director
Investors · 10
Able PartnersNew York City · $500K – $3M
Bantam GroupWestwood
Healthtech CapitalSilicon Valley
iSelect FundSt. Louis · $250K – $2M
Pace VenturesBerlin · $550K – $1.6Mvia Marius Swart · inferred
AlexandriareportedPasadena
Deep FuturereportedSeattlevia Pablos Holman · inferred
Service Provider CapitalreportedVail
SkyRiver Venturesreported · 2 sourcesLexington
Valor Equity Partnersreported · 2 sourcesChicago
Reported raises · per SEC filings
Form D private placements$17.5M disclosed across 4 rounds · 2018–2025
▶$10MraisedJul 2026 · 5 investors · BiotechnologyRule 506(b)
▶$10MraisedJul 2026 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Philip StrandwitzExecutive Officer, Director
- Iain ChessellDirector
- Joan LaRovereDirector
- Michael LaFleurExecutive Officer
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.6MraisedMar 2024 · 19 investors · BiotechnologyRule 506(b)
▶$6.6MraisedMar 2024 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Philip StrandwitzExecutive Officer, Director
- Iain ChessellDirector
- Michael LaFleurExecutive Officer
- Joan LaRovereDirector
- Offering amount
- $9.4M
- Amount sold
- $6.6M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$300KraisedFeb 2021 · 2 investors · BiotechnologyRule 506(b)
▶$300KraisedFeb 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael LafleurDirector
- Kim LewisDirector
- Philip StrandwitzExecutive Officer, Director
- Ian ChessellDirector
- Offering amount
- $2M
- Amount sold
- $300K
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$625KraisedDec 2018 · 1 investors · BiotechnologyRule 506(b)
▶$625KraisedDec 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Phil StrandwitzExecutive Officer, Director
- Michael LafleurDirector
- Kim LewisDirector
- Iain ChessellDirector
- Offering amount
- $1.3M
- Amount sold
- $625K
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
BIOHM22 shared keywordsBIOHM sells probiotic supplements and at-home gut test kits that analyze the microbiome, with results reviewed by a microbiome-trained registered nutritionist who provides personalized diet and supplement recommendations. Its formula combines bacteria, fungi, and a digestive enzyme intended to support digestive health.
Viome17 shared keywordsViome offers at-home tests that analyze the gut and oral microbiome plus cellular blood samples using mRNA/metatranscriptomic sequencing, returning 70+ health scores (including biological age and inflammation) and personalized food and supplement recommendations. The direct-to-consumer service, analyzed in a CLIA-certified lab, is aimed at individuals seeking insights into digestion, metabolism, and overall wellness.
Biomesense7 shared keywordsBiomeSense builds an AI-enabled platform combining hardware (GutLab) and bioinformatics (MetaBiome) to continuously generate and analyze gut microbiome data. It serves scientists, institutions, and companies conducting clinical research on the microbiome for personalized biomarker discovery and product development.
OpenBiome7 shared keywordsOpenBiome Foundation advances microbiome-targeted therapies for serious conditions like Clostridioides difficile through partnerships, innovation funding, and open-access research tools. The organization works to expand patient access to microbiome treatments while accelerating scientific discovery in the field.
Companies competing with Holobiome, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Holobiome, Inc. do?
- Holobiome discovers and develops therapies derived from the human gut microbiome, working to translate microbiome science into probiotics and targeted treatments for whole-body health. The company was founded by research scientists from Northeastern University.
- Who founded Holobiome, Inc.?
- Holobiome, Inc. was founded by Philip Strandwitz, Kim Lewis, Mike La Fleur in 2015.
- Who are Holobiome, Inc.'s investors?
- Holobiome, Inc.'s investors include Able Partners, Bantam Group, Healthtech Capital, iSelect Fund, Pace Ventures, Alexandria, Deep Future, Service Provider Capital and 2 more.
- How much funding has Holobiome, Inc. raised?
- Holobiome, Inc. has disclosed $17.5M raised across 4 rounds.
- Where is Holobiome, Inc. headquartered?
- Holobiome, Inc. is headquartered in Boston, US.